Unknown

Dataset Information

0

Waldenstrom's macroglobulinemia: a clinical perspective in the era of novel therapeutics.


ABSTRACT: Waldenström's macroglobulinemia (WM) is a rare, low-grade malignancy with no established standard of care. Rituximab regimens are most commonly used, supported by their efficacy in hematologic malignancies, including WM. A growing number of investigational regimens for WM have been evaluated in phase II clinical trials, including single-agent and combination strategies that include newer-generation monoclonal antibodies (ofatumumab and alemtuzumab), proteasome inhibitors (bortezomib and carfilzomib), immunomodulatory agents (thalidomide and lenalidomide), phosphoinositide 3-kinase/protein kinase B (Akt)/mammalian target of rapamycin pathway inhibitors (everolimus and perifosene), a Bruton's tyrosine kinase inhibitor (ibrutinib), and a histone deacetylase inhibitor (panobinostat). Other novel agents are in early-stage development for WM. International treatment guidelines for WM suggest suitable regimens in the newly diagnosed and relapsed/refractory settings, in accordance with patient age, disease presentation, and efficacy and safety profiles of particular drugs. These factors must be considered when choosing appropriate therapy for individual patients with WM, to maximize response and prolong survival, while minimizing the risk of adverse events. This review article provides a clinical perspective of the modern management of patients with WM, in the context of available trial data for novel regimens and recently updated treatment guidelines.

SUBMITTER: Dimopoulos MA 

PROVIDER: S-EPMC4722893 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics.

Dimopoulos M A MA   Kastritis E E   Ghobrial I M IM  

Annals of oncology : official journal of the European Society for Medical Oncology 20151123 2


Waldenström's macroglobulinemia (WM) is a rare, low-grade malignancy with no established standard of care. Rituximab regimens are most commonly used, supported by their efficacy in hematologic malignancies, including WM. A growing number of investigational regimens for WM have been evaluated in phase II clinical trials, including single-agent and combination strategies that include newer-generation monoclonal antibodies (ofatumumab and alemtuzumab), proteasome inhibitors (bortezomib and carfilzo  ...[more]

Similar Datasets

| S-EPMC7874350 | biostudies-literature
| S-EPMC9898035 | biostudies-literature
| S-EPMC8925655 | biostudies-literature
| S-EPMC8925683 | biostudies-literature
| S-EPMC3626020 | biostudies-other
| S-EPMC9883164 | biostudies-literature
| S-EPMC9394652 | biostudies-literature
| S-EPMC9098391 | biostudies-literature
2009-08-24 | GSE12668 | GEO
| S-EPMC6717707 | biostudies-literature